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Prevention of chronic kidney disease: A global challenge. In
view of the increasing number of patients requiring renal re-
placement therapy (RRT) every year worldwide, attention has
focused over the last two decades on meeting the health care
need of patients with end-stage renal failure (ESRF). More re-
cently, increasing awareness of the growing burden of chronic
kidney disease (CKD), with a large percentage of the popula-
tion affected by early stages of CKD, has shifted attention and
health care priority to the prevention and early detection of
CKD. This article addresses issues related to general population
as well as targeted screening, favoring the latter. It also examines
some of the screening initiatives undertaken in both the devel-
oping and developed worlds. It also highlights the links between
albuminuria, CKD, and cardiovascular disease (CVD) as an in-
creasing number of studies identify albuminuria/proteinuria, as
well as CKD as major markers of CVD. Finally, a brief review is
included of primary and secondary intervention strategies for
CKD and issues related to their implementation: manpower
and funding.
CHRONIC KIDNEY DISEASE: THE GLOBAL
CHALLENGE
Chronic kidney disease (CKD) is emerging in the
21st century as a global public health issue. Currently,
more than 1 million patients with end-stage renal failure
(ESRF) are on renal replacement therapy (RRT) world-
wide [1], with as many as 2 million predicted to require
therapy by 2010 [1, 2]. The majority of these patients
come from developed nations that can afford the cost of
RRT [3], whereas a large number of those requiring treat-
ment in developing countries do not have access to RRT.
The cost of RRT is prohibitive for many economies and
countries, because there is a clear and direct relationship
between gross national product and availability of RRT
[3, 4]. It is therefore imperative to shift the emphasis of
the global approach to CKD toward early detection and
prevention because management of the growing number
of patents with ESRF may be beyond even the most afflu-
ent of countries. Within the next 10 years, it is estimated
that the annual cost of ESRF management in the United
States will rise to approximately US $30 billion, consum-
ing a considerable part of the health care budget.
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Patients with ESRF are likely to represent the tip of
the iceberg of the entire burden of CKD [5]; it has been
estimated that the number of patients with earlier stages
of CKD (stages 1 to 4) are likely to exceed by as much
as 50-fold that of those reaching ESRF (stage 5). The
Third National Health and Nutrition Examination Sur-
vey (NHANES III) has estimated that 11% (19 million)
of the adult American population has some degree of re-
nal involvement [6]; approximately 11 million individuals
have stages 1 and 2 CKD with glomerular filtration rate
(GFR) exceeding 60 mL/min [6], with another 8 million
with moderate (stage 3) and severe (stage 4) renal in-
sufficiency. By contrast, only 300,000 have reached stage
5 (ESRF). Early detection of CKD and interventions
aimed at preventing its progression into more advanced
stages are likely to be key factors in alleviating the future
burden of ESRF.
It is increasingly recognized that the burden of CKD is
not limited to its impact on demands for RRT but has
major impacts on overall population health. It is now
well established that the prognosis and, in particular,
the cardiovascular morbidity and mortality, of patients
with diabetes mellitus and those with systemic hyperten-
sion depend on renal involvement [7]. Therefore, CKD,
through its impact on cardiovascular risk in these patients,
impacts directly on the global burden of death due to car-
diovascular diseases [7]. Consequently, early detection
and prevention of progressive CKD may not only allevi-
ate the future burden of ESRF but also reduce the cardio-
vascular morbidity and mortality associated with highly
prevalent conditions such as diabetes and hypertension.
CKD DETECTION AND PREVENTION
PROGRAMS
In recent years, a number of screening strategies have
been implemented for the detection of CKD. Some have
focused on the entire population, whereas others targeted
a specific group(s) within the population. General popu-
lation screening approaches have been undertaken in the
United States (NHANES III) [6], Australia [Australian
Diabetes, Obesity and Lifestyle study (AusDiab Study)]
[8], Japan (Okinawa Screening Program) [9], The Nether-
lands [Prevention of Renal and Vascular End-stage
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Disease (PREVEND) Study] [10], Iceland [11], as well
as India [12] and Singapore [13].
NHANES III was carried out in the United States from
1988 to 1994. It involved 15,626 participants and deter-
mined the prevalence of various stages of CKD in the
United States adult population using spot urine albumin
and calibrated serum creatinine levels [6]. It reported that
the overall prevalence of CKD among the population
was 11% (19 million United States adults). It pointed to
a large number (around 6%) of cases of asymptomatic
CKD in the presumably normal general population.
The AusDiab Study was a population-based, cross-
sectional survey to determine the prevalence of diabetes
mellitus, obesity, cardiovascular risk factors, and indica-
tors of kidney disease in Australian adults [8]. A rep-
resentative sample of the Australian adult population
comprising 11,247 participants was studied from May
1999 to December 2000 and showed that 3% of the popu-
lation had proteinuria, whereas 11% were found to have
significant renal impairment (GFR <60 mL/min).
In Japan, the Okinawa screening program carried out
between 1983 and 1984 investigated more than 106,000
individuals followed-up for 17 years [9]. The study iden-
tified initial obesity, dyslipidemia, and smoking as sig-
nificant risk factors for the subsequent development of
albuminuria. It also identified proteinuria [9] and obesity
[14] as major risk factors for the development of CKD.
In Europe, the PREVEND study undertaken in the
Dutch city of Groningen evaluated almost half the pop-
ulation (approximately 40,000 individuals) in a cross-
sectional cohort study [10]. The main objective of
PREVEND was to assess the prevalence of microalbu-
minuria in the general population; the study found that
around 7% of those screened had albuminuria. Individ-
uals with the highest level of albuminuria were found
to have, over a 3-year follow-up period, the highest in-
cidence of cardiovascular death [10]. This observation
highlighted the likely association between albuminuria
and endothelial dysfunction, and atherosclerosis and car-
diovascular morbidity and mortality.
A study in Iceland evaluated 18,912 patients aged 33
to 81 years and found the prevalence of CKD (raised
serum creatinine) very low (0.22%) [11]. This study may
have underestimated the true prevalence of early CKD
because testing that relies on serum creatinine alone is
likely to fail to detect a large number of patients with
CKD and GFRs above 30 mL/min.
The National Kidney Foundation of Singapore set up a
comprehensive program for CKD prevention in 2000 and
is currently evaluating in excess of 450,000 Singapore-
ans [13]. The program detected significant urinary ab-
normalities (ranging from 5% to 8% proteinuria and/or
hematuria) among the general population and high-risk
individuals with a family history of renal insufficiency
[13].
In India, the Chennai community-screening program
screened around 25,000 individuals and found approx-
imately 6% with previously undiagnosed hypertension
and 4% with diabetes mellitus [12]. Subsequently, man-
agement of identified patients with hypertension and di-
abetes with readily available and cheap drugs achieved
target values in the majority of patients [12].
Specific population-targeted approaches have investi-
gated ethnic minorities, such as the Australian Aborig-
ines [15] and the Zuni Indians in the Southwest United
States [16]. Australian Aborigines of the Tiwi Islands
have a high death rate attributable to ESRF [15]. The
annual incidence of ESRF (2760 per million) in Tiwi Is-
landers is among the highest in the world (15 times that
of the general Australian population). This may explain
the very high (5-fold that of the general population) inci-
dence of cardiovascular mortality on this island. The Tiwi
screening program revealed an overall prevalence of al-
buminuria of 55% and, when followed longitudinally, it
highlighted all future risks for renal deaths and cardio-
vascular morbidity and mortality. Of note, intervention in
this high-risk group with angiotensin-converting enzyme
(ACE) inhibition reduced blood pressure, proteinuria,
and overall mortality [15].
The Zuni Kidney Project targeted Zuni Indians in the
United States, where most of the population is affected by
CKD due to glomerulonephritis and diabetic nephropa-
thy, and 2% have ESRF (a staggering prevalence rate
of 17,400 per million population) [16]. The Zuni Kidney
Project showed a prevalence of albuminuria ranging from
12% to 36% among the general population [16].
The National Kidney Foundation of the United States
piloted from 1997 to 1999 the Kidney Early Evaluation
Program (KEEP) to identify individuals at risk of CKD
and the prevalence of CKD among those at risk (pa-
tients with diabetes, patients with hypertension, as well
as first-degree relatives of patients with CKD) [17]. By
the end of 2003, KEEP had recruited over 22,000 partici-
pants and revealed an overall prevalence of the different
stages of CKD in about 50% of those studied. Of these,
26% had albuminuria, around 16% had been found with
elevated serum creatinine levels, and others (3%) had
asymptomatic urinary abnormalities [17].
Different communities probably will have to adopt
different methods that best suit their environment, tak-
ing into consideration such factors as health aware-
ness and availability of human and material resources.
Targeted population screening will suit well-developed
health systems with accurate records and databases.
Whole population surveys will increase health aware-
ness in countries with less-sophisticated health systems
and help detect a significant proportion of underdiag-
nosed individuals with hypertension and diabetes [12].
It may also have the added advantage, as shown in the
Chennai Project in Southern India [12], of improving the
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quality of care of those with diabetes and hypertension,
thus hopefully minimizing their renal and cardiovascular
complications.
CKD AND CARDIOVASCULAR DISEASE:
COMMON RISK FACTORS
The aforementioned screening programs often relied
on urinary albumin measurement to identify individuals
at risk of developing CKD. The prevalence of albumin-
uria in previously healthy individuals varied from 2.4%
to 3% in the AusDiab study [8], 6.3% in NHANES III
[6], and 7% in PREVEND [10]. Higher prevalence was
reported in targeted screening programs; Zuni Kidney
Project: 12% to 36% [16] and KEEP: (26%) [17]. It re-
mains uncertain as to what proportion of patients with
albuminuria will go on to develop CKD with renal insuf-
ficiency.
Beyond its potential for predicting the development
of CKD, albuminuria may also be of value in identify-
ing patients at risk of cardiovascular disease (CVD). Mi-
croalbuminuria is associated with a higher (6- to 8-fold
increase) cardiovascular morbidity and mortality in pa-
tients with diabetes [7, 18, 19]. It has been suggested that
the overall mortality of some groups of patients with di-
abetes is comparable with that of the general population
in the absence of renal involvement. Microalbuminuria is
also a predictor of increased mortality in the elderly [20].
In essential hypertension [21], as in CKD [22], the rate of
decline in renal function is proportional to the severity of
albuminuria/proteinuria.
Testing for microalbuminuria in the absence of associ-
ated risks such as hypertension, diabetes, or old age has
received less attention. The PREVEND study group, us-
ing the albumin concentration of a spot morning urine
sample, noted that urinary albumin excretion is associ-
ated with renal functional abnormalities in a nondiabetic
or hypertensive population [23]. The study also observed
a link between microalbuminuria and cardiovascular as
well as all-cause mortality in the general population [19,
23].
A growing body of evidence suggests that conventional
risk factors for CVD are also associated with increased
risk of CKD [24]. The Framingham Offspring Study in-
vestigated predictors of new onset CKD in 2585 healthy
participants who attended a baseline examination from
1978 to 1982 and a follow-up examination from 1998 to
2001 [25]. Two hundred forty-four (9.4%) of those studied
developed CKD. Identifiable risk factors were increasing
age [odds ratio (OR) = 2.36 per 10-year increment], in-
creased body mass index (OR = 2.60), diabetes (OR =
2.38), smoking (OR = 1.42), and hypertension (OR =
1.57). Those with impaired kidney function at the onset
also were at higher risk.
The Okinawa study of over 100,000 individuals iden-
tified obesity, smoking, and hypertriglyceridemia as pre-
dictors of albuminuria over a 10-year observation period
[9]. Proteinuria [26] as well as obesity [14] also predicted
the development of ESRF.
The Multiple Risk Factors Intervention Trial (MRFIT)
of over 300,000 male United States citizens made similar
observations, identifying hypertension, obesity, and hy-
perlipidemia as risk factors for the development of CKD
[27].
The Washington County survey in Maryland, United
States, of 23,534 men and women over a 20-year pe-
riod identified baseline blood pressure, cigarette smoking
(hazard ratio: 2.4 in men and 2.9 in women), and treated
diabetes (hazard ratio: mean: 5 and women: 10.7) as risk
factors for the development of CKD [28].
Undoubtedly, common risk factors appear to predis-
pose to both renal and cardiovascular diseases in devel-
oped countries. Early detection and prevention may have
an impact on the outcome of both renal and cardiovas-
cular morbidity and mortality. These may also be of rel-
evance to the increasingly westernized societies of the
emerging world. Westernized and urbanized societies in
emerging countries may be acquiring a similar risk profile
to that of the developed world, with diabetes and hyper-
tension leading the risk factors for CKD.
Also, developing countries continue to suffer from the
massive burden of infectious diseases and infestations
with their associated renal involvement. The global bur-
den of human immunodeficiency virus, with 40 million
infected individuals [29], hepatitis C virus (170 million)
[30], malaria (300 million cases per year) [31], schisto-
somiasis (200 million) [32], as well as tuberculosis (200
million) [33], is compounded by the high incidence of
CKD in affected individuals. This, in turn, increases the
morbidity and mortality associated with these infections
worldwide. Detection and prevention of CKD programs
in the emerging world have to take the infectious disease
burden in mind.
CKD: SCREENING APPROACHES
Pitfalls of measurement of albuminuria/proteinuria
Many of the above-mentioned studies have relied on
measurement of urinary albumin or protein for the detec-
tion of patients at risk for CKD. Some have questioned
the value of mass population screening for proteinuria,
reasoning that its yield of treatable diseases, especially in
young adults, is too low to be justifiable [34]. Orthostatic
proteinuria, diet, menstruation, transient fever, hydration
status, and physical activity are all factors that may affect
the level of proteinuria and undermine the outcome of an
untargeted randomly selected mass proteinuria screening
exercise. The assessment of proteinuria as a marker of
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CKD can be limited by the potential for misclassification
of individuals because of variability of protein levels in
the individual’s urine over time and the extent to which
conditions at that time may obscure the true level. Of
note, in the NHANES III survey, only 63% of the initial
positive results of microalbuminuria could be confirmed
on repeat testing [6], thus indicating that one spot test
may overestimate the prevalence of albuminuria. Vari-
ability of urine albumin excretion rates with age was also
demonstrated in NHANES III, with abnormal albumin-
uria rates varying from 7% in the group that was 20 to
39 years of age to about 30% in the group that was more
than 70 years of age in the general population [35].
Furthermore, besides diabetic nephropathy, little is
known of the renal outcome of patients with isolated
microalbuminuria. The Nord-Trondelag Health Study in
Norway (HUNT) demonstrated that 3 positive urine sam-
ples for elevated albumin/creatinine ratio were superior
to a fewer number of samples in predicting proteinuria
[36]. A timed 24-hour urine albumin excretion rate, con-
sidered the most accurate method of albuminuria esti-
mation, reasonably eliminates the variability of urinary
albumin concentration due to activity and posture. How-
ever, such approach is limited because it is an ardu-
ous task for the patient and there are inaccuracies in
the urine collection. The Nord-Trondelag Health Study
(HUNT) group concluded that in a randomly selected
apparently healthy population, as a result of low-positive
predictive value and reduced reliability, microalbumin-
uria did not satisfy the criteria for a good screening test
[37].
Therefore, it has been suggested that rather than
screening for albuminuria alone, albuminuria and hema-
turia should be tested for in combination, and may be
more powerful in predicting renal parenchymal damage
than proteinuria alone [38].
The KEEP study group’s set objective of targeting the
population with known risk factors for kidney disease by
screening with the aim of maximizing yield is a pragmatic
approach to the issue of population screening [17]. The
effectiveness of targeted screening was shown by com-
paring the results of KEEP (elevated serum creatinine:
5.4%) with those of other similar studies for the same
United States population (NHANES III: 3%).
In Western nations, where diabetes and hypertension
account for more than 50% of cases of ESRD, care of
patients will increasingly depend on primary care physi-
cians. Consequently, there is a need for clear and unam-
biguous guidelines that can be applied universally. It has
been argued that emphasis on the prevention of ESRD
should be directed toward such high-risk groups for max-
imum yields, and that screenings should be carried out
at regular intervals. On the other hand, mass population
screening may be less cost effective [17].
The strategic approach to screening in developing
countries requires special attention. Lifestyle changes
that affect the developing world will have a major impact
on cardiovascular as well as renal morbidity and mortal-
ity rates in years to come. Population education initia-
tives and programs aimed at early detection of diabetes
and hypertension and their management are warranted
and will have to engage health care agencies and orga-
nizations. They will also require the full commitment of
governments and their agencies in those countries.
CKD DETECTION AND PREVENTION
PROGRAMS: A GLOBAL APPROACH
Lifestyle modification
In addressing challenges posed by the worldwide CKD
pandemic, diet and lifestyle modifications, and the tight
control of diabetes and hypertension are imperative,
stressing patency policies that keep highly effective drugs
out patients’ reach, should be given greater consideration
and urgency.
Increasing evidence suggests that lifestyle modifica-
tions such as weight reduction, exercise, and dietary ma-
nipulations can be effective and protective. A number
of trials have shown that lifestyle modifications (weight
reduction with or without regular exercise) can consider-
ably reduce the incidence of type 2 diabetes in overweight
individuals with impaired glucose tolerance [39, 40]. Di-
etary approaches to reduce blood pressure consisting of
dietary salt restrictions as well as diets rich in fruit and
vegetables and low in saturated fat have proved effec-
tive. This was examined in the Dietary Approaches to
Stop Hypertension-Sodium Trial [41, 42]. Undoubtedly,
improved population health with reduction of excessive
weight, regular exercise, and dietary approaches will lead
to a reduction in the growing number of patients with di-
abetes and hypertension in the long run. This is likely to
have a major impact on the incidence of CKD and asso-
ciated CVD.
Smoking has been implicated in the onset of microal-
buminuria in individuals with and without diabetes [43].
Cessation of smoking will undoubtedly be beneficial in
individuals at risk of renal disease as well as CVD. Alco-
hol has been linked with the development of ESRF, and
it may also increase cardiovascular risks through hemo-
dynamic effects on systemic blood pressure [44].
Pharmacologic approaches
Control of hypertension is the single most important
intervention to reduce both albuminuria/proteinuria and
subsequent development of CKD in patients with and
without diabetes alike [45]. It is therefore imperative
to detect prehypertensive states, aim at lower blood
pressure levels in the general population, and be even
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more aggressive with lowering blood pressure in pa-
tients with hypertension and underlying CKD [46]. It
has been suggested that every elevation of systolic blood
pressure above 115 mm Hg in the general population is
associated with a doubling of the risk of CVD. In patients
with CKD, target blood pressure levels should be less than
130/80 mm Hg in the absence of diabetes or proteinuria
and <125/75 mm Hg in patients with diabetes and those
with proteinuria in excess of 1 g/24 h [46].
The control of glycemia has been shown to be a ma-
jor factor in the prevention and progression of diabetic
nephropathy [47–49]. Target glycosylated hemoglobin
levels around 7% have been recommended. Realistically,
levels consistently less than 8% should be protective
without exposing patients to the risks of hypoglycemic
complications.
Control of albuminuria/proteinuria is also an impor-
tant factor in slowing the progression of diabetic and
nondiabetic CKD [50, 51]. For that reason, antihyper-
tensive approaches using ACE inhibitors or angiotensin
receptor blockers have been widely advocated [52].
Their impact on renal function is often proportional to
their proteinuria-lowering effect. Inhibition of the renin-
angiotensin-aldosterone system may also have additional
renoprotective effects through inhibition of renal inflam-
mation and fibrosis. Furthermore, these agents are also
known to be cardioprotective and may therefore mini-
mize cardiovascular complications of CKD.
Dyslipidemia has been implicated in progression of
CKD. Subsequently, lipid reduction with HMG CoA re-
ductase inhibitors (statins) has been shown to be protec-
tive in experimental CKD and may have additive effects
when combined with inhibitors of the rennin-angiotensin-
aldosterone system [53]. A systematic review of lipid-
lowering trials in CKD suggested a potential benefit in
slowing the rate of progression of chronic kidney failure
[54]. The cardioprotective potential of statins is now well
established.
In light of the above, the concept of multiple drug ther-
apy has been put forward after a meta-analysis of over
750 trials involving around 400,000 participants suggested
that up to 80% reduction in CVD events can be obtained
by a combination treatment of a polypill containing an
ACE inhibitor, a statin, and other cardioprotective agents
such as aspirin and vitamins [55]. A similar therapeutic
approach may be adoptable in the future in selected pa-
tients with progressive CKD in an attempt to prevent the
development of progressive renal insufficiency and asso-
ciated cardiovascular complications. This may be a prag-
matic and cost-effective approach to reduce the global
burden of renal and CVD. For that well-defined popula-
tion, screening programs have to be initiated to identify
at-risk individuals, along with the application of the afore-
mentioned early and systematic preventive treatment
approaches.
MANPOWER TO IMPLEMENT CKD
PREVENTION AND PREVENTION PROGRAMS
Detection and prevention of CKD programs require
considerable resources both in terms of manpower and
funds. Availability of such resources will depend primar-
ily on the leadership of nephrologists worldwide. It will
also depend on the training and availability of a new gen-
eration of dedicated nephrologists with an interest and
training in epidemiology and public health issues. For
that, nephrology training programs will have to be tai-
lored in the future to the requirements of the commu-
nity in which the nephrologist will practice. The Sheffield
Kidney Institute in the UK has a longstanding track
record in training nephrologists from developing coun-
tries. Recent emphasis has shifted to acquiring more
epidemiology, biostatistics, and public health knowl-
edge. Nephrologists have also been encouraged to ac-
quire the necessary skills to set up relevant databases
and registries. The European Kidney Institute was
founded in 2004 and brings together the expertise of
nephrologists from the Mario Negri Insitute (Berg-
amo, Italy), the Groningen Research Institute for Kid-
ney Disease (Groningen, The Netherlands), and the
Sheffield Kidney Institute (Sheffield, United Kingdom)
to provide a European-training infrastructure capa-
ble of supporting detection and prevention projects
worldwide.
Nephrologists will have to rely on well-trained and
motivated community health workers. Such a multi-
disciplinary approach has proved effective and suc-
cessful when applied in projects such as that of the
Chennai Community Screening project in India [12]
or of the Tiwi Islanders in Australia [15]. In both,
nephrology leadership, along with a dedicated commu-
nity health care force, proved a powerful and successful
combination.
FUNDING OF CKD DETECTION AND
PREVENTION PROGRAMS
Funding of detection and prevention of CKD programs
will have to engage governments, nongovernmental and
charitable organizations, as well as the pharmaceutical
industry. Commitment of local governmental agencies at
regional and national levels is a prerequirement to the im-
plementation of many such initiatives. Nongovernmental
and charitable organizations have an important role to
play in lobbying and encouraging governments to take
up and support such programs. Finally, the pharmaceu-
tical industry will have to face up to its responsibilities
in supporting such detection of CKD programs, knowing
that many patients identified will undoubtedly require
their products to prevent progression of underlying kid-
ney diseases [56].
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CONCLUSION
A multifaceted approach is urgently needed to stem the
global tide of ESRF. This calls for concerted efforts from
governmental agencies, international bodies, and orga-
nizations, including the pharmaceutical industry. It calls
for a rethinking of medical and nephrologic training and
that of associated health workers to meet community-
based demands. Ultimately, population-increased educa-
tion and awareness will contribute to its well-being.
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